Please login to the form below

Not currently logged in
Email:
Password:

Double-dose of cancer drug fails to meet target

Novartis has failed to prove that higher measures of its cancer drug, Glivec are more effective than the current dosage
Novartis has failed to prove in clinical trials that higher measures of its cancer drug, Glivec are more effective than the current dosage.

Trials of 800mg doses of Glivec in patients with chronic myeloid leukaemia (CML), showed no statistically significant improvement to patients treated with the standard 400mg dose.

The higher dose did however have an effect when used as the primary treatment for newly diagnosed patients with clinical milestones achieved significantly faster than with the 400mg dose.

"[The trial] reaffirms Glivec as the standard of care for newly diagnosed CML patients," said Dr Jorge Cortes, professor of medicine and deputy chair of Leukemia at the University of Texas. "We see a strong trend for rapid response with the 800mg doseÖ further follow up will be needed to assess what this rapid early response will mean in terms of long-term benefit."

13th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics